MichaelD.GeschwindMDPhD, FAAN, FANA

Neurology • San Francisco, CA

Professor of neurology and holds the Michael J. Homer Chair in Neurology in the UCSF School of Medicine

Join to view full profile

Dr. Geschwind is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Geschwind's full profile

Already have an account?

Office
1651 4th Street, Suite 212
San Francisco, CA 94158
Phone+1 415-353-2057

Fax+1 415-353-8292

Summary

Dr. Michael Geschwind is a neurologist in San Francisco, CA and is affiliated with multiple hospitals in the area, including UCSF Medical Center and Zuckerberg San Francisco General Hospital and Trauma Center. He received his medical degree from Albert Einstein College of Medicine and has been in practice 20 years. He is experienced in prion diseases, spinocerebellar ataxia, dementia, autoimmune neurology, and huntington's disesae.

Education & Training

Johns Hopkins UniversityResidency, Neurology, 1997 - 2000
UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1996 - 1997
Albert Einstein College of MedicineClass of 1996

Certifications & Licensure

CA State Medical License 2000 - 2024
FL State Medical License 2016 - 2018
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Neurobiological Predictors of Huntington's Disease (PREDICT-HD) Start of enrollment: 2002 Aug 01
Active, not recruiting
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease Start of enrollment: 2005 Sep 01
Completed
Phase 3
CJD (Creutzfeldt-Jakob Disease) Quinacrine Study Start of enrollment: 2005 Apr 01
Completed
Phase 2
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease Start of enrollment: 2006 Oct 01
Completed
Phase 1, Phase 2
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias Start of enrollment: 2010 Apr 01
Recruiting
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease Start of enrollment: 2010 Feb 01
Terminated
Phase 3
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Recruiting
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod Start of enrollment: 2014 Oct 28
Completed
Phase 2
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi Start of enrollment: 2015 Jul 01
Completed
Phase 2
Trial in Adult Subjects With Spinocerebellar Ataxia Start of enrollment: 2016 Dec 15
Active, not recruiting
Phase 2, Phase 3
Clinical Trial Readiness for SCA1 and SCA3 Start of enrollment: 2018 Aug 16
Active, not recruiting
Troriluzole in Adult Subjects With Spinocerebellar Ataxia Start of enrollment: 2019 Mar 08
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

556 citations
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Michael G. Erkkinen, Mee Ohk Kim, Michael D. Geschwind
Cold Spring Harbor Perspectives in Biology. 2018-04-01
532 citations
AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location
Meizan Lai, Ethan G. Hughes, Xiaoyu Peng, Lei Zhou, Amy J. Gleichman
Annals of Neurology. 2009-04-01
196 citations
Encephalitis and AMPA receptor antibodies Novel findings in a case series of 22 patients
Romana Höftberger, Agnes van Sonderen, Frank Leypoldt, David J. Houghton, Michael D. Geschwind
Neurology. 2015-06-16

Journal Articles

Neuroimaging in Dementia
Michael D Geschwind, Fanny M Elahi, Christopher P Hess, Seminars in Neurology

Press Mentions

146th Annual Meeting of the American Neurological Association to Focus on Research and Development of Neurologic Disease TherapeuticsOctober 5th, 2021
Police Have Investigated Five Cases in Five Years of Dementia Sufferers Causing Fatal Injuries to OthersMay 24th, 2019
The Eyes Have ItNovember 20th, 2018
Join now to see all

Grant Support

Predicting progression of human prion diseaseNIA2013–2018
Early Diagnosis Of Human Prion DiseaseNational Institute On Aging2008–2011
New Clinical Approaches To Creutzfeldt-Jakob DiseaseNational Institute On Aging2003–2007